Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sciele And Addrenex Seek Hypertension Approval For Sustained-Release Clonidine

This article was originally published in The Pink Sheet Daily

Executive Summary

The 12-hour formulation is designed to improve clonidine’s side effect profile.

You may also be interested in...



Sciele, Addrenex Partner On Novel Hypertension Drug

Alpha adrenergic receptor agonist will enter Phase II clinical studies in the second half of the year.

Sciele, Addrenex Partner On Novel Hypertension Drug

Alpha adrenergic receptor agonist will enter Phase II clinical studies in the second half of the year.

Sciele Pharma Will Market Clonicel Under Addrenex Deal

Addrenex will submit NDA for sustained-release clonidine for hypertension later this year, followed by application for ADHD.

Related Content

Topics

UsernamePublicRestriction

Register

PS067277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel